Related references
Note: Only part of the references are listed.Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
C. Roux et al.
BONE (2014)
Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy A Randomized Open-Label Trial
Chris Recknor et al.
OBSTETRICS AND GYNECOLOGY (2013)
Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates
Kristi Reynolds et al.
ANNALS OF PHARMACOTHERAPY (2012)
Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data
David W. Dempster et al.
CLINICAL THERAPEUTICS (2012)
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
Matthew Austin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System
J. Devine et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody
Paul J. Kostenuik et al.
BONE (2011)
Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys
Michael S. Ominsky et al.
BONE (2011)
Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk
S. Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009
S. Lee et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence
Becky A. Briesacher et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density
H. K. Genant et al.
BONE (2010)
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy
David L. Kendler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Microarchitectural Deterioration of Cortical and Trabecular Bone: Differing Effects of Denosumab and Alendronate
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis
F. -E. Cotte et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe
Ethel S. Siris et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization
J. A. Sunyecz et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Risk factors for vertebral and nonvertebral fracture over 10 years: A population-based study in women
Judith Finigan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Michael McClung et al.
BONE (2007)
Fracture risk and antiresorptive medication use in older women in the USA
S. H. Gehlbach et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population
KF Huybrechts et al.
BONE (2006)
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women
RR Recker et al.
MAYO CLINIC PROCEEDINGS (2005)
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
JJ Caro et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Share Paper
